China Resources Double-Crane

China Resources Double-Crane Pharmaceutical Co., Ltd. boasts 83 years of brilliant history, originating in 1939 as a military pharmaceutical factory born in the Taihang Mountain revolutionary base, externally known as Lihua Pharmaceutical Factory. In 1949, it moved to Beijing with the army and was later renamed Beijing Pharmaceutical Factory, developing into a large state-owned comprehensive chemical pharmaceutical enterprise, laying the foundation for Beijing's modern chemical pharmaceutical industry. It went public on the Shanghai Stock Exchange in 1997 and expanded externally to become a cross-regional group based in Beijing and radiating throughout China. In 2010, it joined China Resources Group, a Fortune Global 500 company, and is now one of the business units in the group’s healthcare sector. The company owns 21 subsidiaries and more than 11,000 employees. Its main businesses cover new drug R&D, formulation production, pharmaceutical sales, pharmaceutical equipment, and active pharmaceutical ingredient production. It has a rich product portfolio, high-quality products, cost control, strong channel and terminal coverage and management capabilities, good brand advantages and internationalization strengths, a dynamic team, and profound corporate culture. Its economic strength, competitive vitality, and sustainable development capabilities rank among the top domestic pharmaceutical companies. In 2021, it achieved main business revenue of 9.03 billion yuan and net profit (attributable to parent company) of 940 million yuan. The company actively deploys four major business platforms: generic drugs, infusion products, differentiated drugs, and innovative drugs. It focuses on chronic diseases, infusion products, pediatrics, nephrology, psychiatry/neurology, and other fields. Nineteen key products, such as 0#, Guanshuang, Yashida, Suiyue, Tangshiping, BFS Infusion, Kelisu, Peritoneal Dialysis Solution, and Magnesium Valproate Sustained-Release Tablets, each have annual sales exceeding 100 million yuan. It owns well-known Chinese trademarks like "Double-Crane and Logo," "Saike," and "Xiangzhong," and has received numerous honors including "Top 100 Chemical Pharmaceutical Enterprises in China," "Top 100 Comprehensive Strength Industrial Enterprises in China’s Chemical Pharmaceutical Industry," "National High-tech Enterprise," and "Beijing Municipal Government Quality Management Award."